Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index - Scorecard - MDSpire
Advertisement
Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index
Clinical Scorecard: Prognostic Significance of Organ Involvement in Aggressive Adult T-Cell Leukemia/Lymphoma: Establishing Risk Organ Criteria and a New Prognostic Index
At a Glance
Category
Detail
Condition
Aggressive Adult T-cell leukemia/lymphoma (ATL)
Key Mechanisms
Tumorigenesis of HTLV-1-infected T lymphocytes with extranodal organ involvement impacting prognosis
Target Population
Patients diagnosed with aggressive ATL, predominantly stage IV
Care Setting
Systemic therapy including chemotherapy and allogeneic hematopoietic cell transplantation (allo-HCT)
Key Highlights
Lung, liver, and CNS involvement identified as risk organs significantly associated with poor overall survival (OS).
Number of involved organs correlates negatively with OS; ≥6 organ lesions linked to markedly worse prognosis.
Risk organ involvement remains an independent prognostic factor beyond established indices and clinical variables.
Guideline-Based Recommendations
Diagnosis
Define organ involvement by pathological evidence, abnormal imaging, or organ dysfunction responsive to ATL treatment.
Assess involvement of peripheral blood, bone marrow, lymph nodes, skin, lung, liver, spleen, CNS, and other organs.
Management
Intensive systemic therapy including VCAP-AMP-VECP chemotherapy regimen.
Consider allogeneic hematopoietic cell transplantation (allo-HCT) for eligible patients, noting reduced allo-HCT rates in CNS and lung involvement.
Monitoring & Follow-up
Evaluate number and specific sites of organ involvement to stratify prognosis and guide treatment intensity.
Monitor performance status (ECOG PS) as it correlates with organ involvement and treatment eligibility.
Risks
Poor ECOG PS and risk organ involvement (lung, liver, CNS) predict lower likelihood of receiving allo-HCT and worse survival outcomes.
High burden of organ lesions (≥6) associated with significantly reduced median OS.
Patient & Prescribing Data
140 patients with aggressive ATL, median age 62, 99% stage IV, 85% acute-type
65% received VCAP-AMP-VECP as initial therapy; 59% underwent allo-HCT; CNS and lung involvement patients less likely to receive allo-HCT due to poor performance status
Clinical Best Practices
Incorporate assessment of lung, liver, and CNS involvement into prognostic evaluation for aggressive ATL.
Use risk organ involvement alongside existing prognostic indices for refined risk stratification.
Prioritize supportive care to improve ECOG performance status to increase eligibility for allo-HCT.
Recognize that splenic involvement often co-occurs with risk organ involvement but is not an independent risk factor.
